Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lupus

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

- PMLiVE

Allergan buys two NASH drug developers in one day

More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics

- PMLiVE

GSK and J&J file sirukumab for rheumatoid arthritis in EU

If approved it will compete with Roche blockbuster Actemra

- PMLiVE

Biogen launches Remicade biosimilar in the UK

Flixabi provides another low-cost alternative to J&J’s biggest-selling drug

Novartis day

Novartis claims first place for its biosimilar Enbrel in US

However, Amgen’s patent infringement lawsuit could delay the launch of Erelzi

Gilead Sciences

Gilead’s Truvada cleared for HIV prevention in EU

May help slow down recent uptick in new HIV diagnoses

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

- PMLiVE

ViiV takes two-drug cocktail for first-line HIV into phase III

New approach hopes to reduce drug exposure and improve adherence

- PMLiVE

Lupus trial hailed as a success despite patient deaths

Phase IIb trial of Aurinia Pharmaceuticals’ voclosporin met its objective

- PMLiVE

Pfizer closes on Xeljanz filing in ulcerative colitis

Latest positive data could help the slow-growing drug meet blockbuster sales expectations

- PMLiVE

Gilead’s universal hep C therapy Epclusa approved in EU

European nod for first pan-genotypic treatment follows recent FDA licensing

National Institute for Health and Care Excellence NICE logo

NICE approves UCB Pharma’s Cimzia

New guidance could significantly extend the patient population it could treat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links